Dyax Launches HAE Diagnostic Testing Refund Program to Encourage Proper Diagnosis and Disease Management
Business Wire, Inc. |
There are several programs currently available to financially assist patients already diagnosed with HAE. This program, the first of its kind in HAE, will lower financial hurdles for eligible patients seeking HAE diagnostic testing.
“Healthcare should not be limited by affordability,” said
"The HAEA appreciates Dyax’s continuing efforts to encourage early HAE patient diagnosis and management”, said
Patients can enroll in the program by calling 855-HAE Hope (855-423-4673) or by visiting http://www.haehope.com/haetesting. The HAE diagnostic testing refund program is just part of a suite of services that
About HAE
Hereditary angioedema (HAE) is a rare acute inflammatory condition characterized by episodes of severe, often painful swelling affecting the extremities, gastrointestinal tract, genitalia, and larynx. HAE is caused by low or dysfunctional levels of C1 esterase inhibitor (C1-INH), a naturally occurring molecule that inhibits plasma kallikrein, a key mediator of inflammation, and other serine proteases in the blood. HAE is estimated to affect 1 in 10,000 to 1 in 50,000 individuals. Learn more at www.HAEHope.com.
About KALBITOR® (ecallantide)
KALBITOR is a plasma kallikrein inhibitor indicated for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older. KALBITOR, which was discovered and developed by
Important KALBITOR Safety Information
Anaphylaxis has been reported after administration of KALBITOR. Because of the risk of anaphylaxis, KALBITOR should only be administered by a healthcare professional with appropriate medical support to manage anaphylaxis and hereditary angioedema. Healthcare professionals should be aware of the similarity of symptoms between hypersensitivity reactions and hereditary angioedema and patients should be monitored closely. KALBITOR should not be administered to patients with known clinical hypersensitivity to KALBITOR.
For more information about KALBITOR, including full prescribing information, visit www.KALBITOR.com.
About
Founded and staffed by HAE patients and caregivers, the
About
Ecallantide and other compounds in Dyax’s pipeline were identified using its patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets.
Executive Vice President and Chief Financial Officer
[email protected]
or
Manager, Investor Relations and
[email protected]
Source:
Copyright: | Copyright Business Wire 2012 |
Wordcount: | 814 |
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News